[{"uuid": "a652b6a5-9954-33bd-9ca9-b5aecbad37d6", "title": "Exact Sciences Schedules Fourth Quarter 2024 Earnings Call", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/exact-sciences-schedules-fourth-quarter-110000499.html", "providerPublishTime": 1738580400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/fw812b63vBB2zSsmtRO_hA--~B/aD0yNDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b7a5618d491d86ff2d3d712ad73cfc26", "width": 480, "height": 241, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Yq.xlNmV0hOik8NsxSam1A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/b7a5618d491d86ff2d3d712ad73cfc26", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXAS"]}, {"uuid": "c48bde3a-d3a6-34d8-a9a3-5b33c4db86d0", "title": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/2-medical-stocks-could-beat-140009669.html", "providerPublishTime": 1738072809, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/132juehTNIyEUn7pK7.GPA--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619", "width": 900, "height": 506, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/twDpSkUZEyzUBc0qEMHAqw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXAS", "GH"]}, {"uuid": "cd430ea6-3623-3b0d-bca4-9a2df1b6183d", "title": "Barclays Initiates Exact Sciences at Overweight", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/barclays-initiates-exact-sciences-overweight-131527638.html", "providerPublishTime": 1737638127, "type": "STORY", "relatedTickers": ["EXAS"]}, {"uuid": "9632f317-bf9c-3d43-aca8-83ac69ace0da", "title": "Netflix upgraded, Electronic Arts downgraded: Wall Street's top analyst calls", "publisher": "The Fly", "link": "https://finance.yahoo.com/news/netflix-upgraded-electronic-arts-downgraded-143522060.html", "providerPublishTime": 1737642922, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/zUit8GQVW5kcaTZHEPMI9Q--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec", "width": 1200, "height": 628, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/IPH9wCP.ftudEFOX7xr1MA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EA", "NFLX"]}, {"uuid": "68a66af1-bf64-359f-950b-631455d79355", "title": "Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/exact-sciences-demonstrates-leadership-cancer-220500090.html", "providerPublishTime": 1737497100, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ZDa4vOtsD5UWbyS4est7pg--~B/aD0yNDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/97d591c85bae3fa3e4c25934bbd7b08f", "width": 480, "height": 241, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/rGOyq4vohShTiIOvVsgcVw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/97d591c85bae3fa3e4c25934bbd7b08f", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXAS"]}, {"uuid": "78046a49-515d-3175-90e1-ffc454f42817", "title": "New Evidence Validates Oncodetect's\u2122 Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/evidence-validates-oncodetects-ability-detect-220500351.html", "providerPublishTime": 1737497100, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/jjUqJjZs7cVVPCc2uTzQ.w--~B/aD0yNDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/69893946b5359ab9c5217f49b8e05bdc", "width": 480, "height": 241, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/SBJIZV4BV32g8c.0HzlUtw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/69893946b5359ab9c5217f49b8e05bdc", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXAS"]}, {"uuid": "77d885b2-571b-357b-8283-2ea2a3e32134", "title": "Exact Sciences post positive results from MRD trial", "publisher": "Clinical Trials Arena", "link": "https://finance.yahoo.com/m/77d885b2-571b-357b-8283-2ea2a3e32134/exact-sciences-post-positive.html", "providerPublishTime": 1737549566, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Fke_r2qROoaJcJbZgdaATA--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/f46da9cb1f5ea01d651dbe768faa6317", "width": 1440, "height": 810, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/lxtSwfgp74vxTqDbePH0JA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/f46da9cb1f5ea01d651dbe768faa6317", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXAS"]}, {"uuid": "a4ab74fc-9616-3a24-83be-3954e8fcb4ba", "title": "Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone", "publisher": "Investor's Business Daily", "link": "https://finance.yahoo.com/m/a4ab74fc-9616-3a24-83be-3954e8fcb4ba/why-top-4%25-guardant-health.html", "providerPublishTime": 1737493416, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/pkMoLO.pyfSp54cgQiV6MQ--~B/aD01MzM7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/7cf647cbaae0a9ebd82db6130cd3aff5", "width": 945, "height": 533, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/_it32F4gjkE6wd8sJu8w4w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/7cf647cbaae0a9ebd82db6130cd3aff5", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GH", "EXAS", "NTRA"]}, {"uuid": "632d8ad3-f627-34a9-8dc3-a247620916f9", "title": "Why Exact Sciences (EXAS) Is Crashing?", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/why-exact-sciences-exas-crashing-111530738.html", "providerPublishTime": 1737112530, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/BP6lCyvQrUJKyb1deM.c3A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8230cd721248043c3c5362450f0af7cc", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zFzAwv0VLpJHA1h4LC1yeA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8230cd721248043c3c5362450f0af7cc", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXAS"]}, {"uuid": "1a527746-2945-340f-af68-76b691837c48", "title": "2 Healthcare Stocks to Buy Hand Over Fist in January", "publisher": "Motley Fool", "link": "https://finance.yahoo.com/m/1a527746-2945-340f-af68-76b691837c48/2-healthcare-stocks-to-buy.html", "providerPublishTime": 1737022920, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/HKQ.2u5djMzgrTzRw7By4A--~B/aD0xNDE0O3c9MjEyMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/50b003f9d19d495dba849046acfa1425", "width": 2121, "height": 1414, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/BXalew1nq9KMGrKAIynZNg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/50b003f9d19d495dba849046acfa1425", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DXCM", "EXAS"]}, {"uuid": "3e095b46-f3fe-38cf-b64c-5c898e455f2a", "title": "Exact Sciences Stock Drops 11% Over Four Days. 'What Is Going On?'", "publisher": "Investor's Business Daily", "link": "https://finance.yahoo.com/m/3e095b46-f3fe-38cf-b64c-5c898e455f2a/exact-sciences-stock-drops.html", "providerPublishTime": 1737061513, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/sOnQOK4D2pilBYgsDhm_KA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/2ad36331caf8055618f5bbcee86f6c9a", "width": 1000, "height": 563, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/WuTJqwcy7HTBDGr1AacPEg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/2ad36331caf8055618f5bbcee86f6c9a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXAS", "NTRA", "GH"]}, {"uuid": "40dfe6e9-6acd-3fb6-9551-ed9959f7e97e", "title": "Exact Sciences Expects 10% Growth in Q4 Revenue", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/exact-sciences-expects-10-growth-085243237.html", "providerPublishTime": 1736758363, "type": "STORY", "relatedTickers": ["EXAS"]}, {"uuid": "452adb3e-7c1b-37c3-bf9c-15d5fe3248a5", "title": "High Growth Tech Stocks To Watch In January 2025", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/high-growth-tech-stocks-watch-141144046.html", "providerPublishTime": 1736863904, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/eZ0FiSKCVDYnTK6X1bRieQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXAS", "VCEL", "SEMR"]}, {"uuid": "d7f62444-c817-3223-b45d-3ffaf0d4c8fd", "title": "Exact Sciences Announces Preliminary Fourth Quarter 2024 Results", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/exact-sciences-announces-preliminary-fourth-000000268.html", "providerPublishTime": 1736726400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/mTZvHmgtKohqjF.3RENPeg--~B/aD0yNDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d589ef9cba6a8200072e790550e50bf7", "width": 480, "height": 241, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/9c7pb7bU6cPTaXqPLEkqPQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d589ef9cba6a8200072e790550e50bf7", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXAS"]}, {"uuid": "0b222a24-9b4e-33fa-9ede-d45166b07317", "title": "Should Exact Sciences Stock Stay in Your Portfolio Right Now?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/exact-sciences-stock-stay-portfolio-120200686.html", "providerPublishTime": 1736337720, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/IYksUEF.ZX5JOPFmQ194jQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXAS", "HAE"]}, {"uuid": "e258e499-21a8-3308-8a5d-b9d38c4eeda6", "title": "Exact Sciences price target raised to $70 from $60 at Evercore ISI", "publisher": "TipRanks", "link": "https://finance.yahoo.com/news/exact-sciences-price-target-raised-114623940.html", "providerPublishTime": 1735904783, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ShAwIQ85SkA_hiR9ajTS9A--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/bd23518bddbecaa2e26b66cd7da7f21e", "width": 192, "height": 192, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/vx7Ki8YEnr5LZSuutkC7jQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/bd23518bddbecaa2e26b66cd7da7f21e", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXAS"]}, {"uuid": "63c99c5b-e4a3-31cf-be3f-207dededcfbe", "title": "Exact Sciences to Participate in J.P. Morgan Healthcare Conference", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/exact-sciences-participate-j-p-110000908.html", "providerPublishTime": 1735815600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/5sWmVcYCSai2LrZkqLK8yA--~B/aD0yNDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/17fa9da5f275a07f68690bf7d36e15ae", "width": 480, "height": 241, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/4LTj4R9Q6th5bCQXE0AxIA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/17fa9da5f275a07f68690bf7d36e15ae", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXAS"]}, {"uuid": "22c0696b-c62d-377a-a4d0-90f268a77ef8", "title": "EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/exas-stock-set-benefit-favorable-120700720.html", "providerPublishTime": 1731931620, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/n5SbNKsJsCKv7joAIRd2zA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXAS", "GMED", "HAE"]}, {"uuid": "acde290a-5c0b-35a1-8daa-771a95573da0", "title": "Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/exact-sciences-corporation-exas-among-235759324.html", "providerPublishTime": 1732060679, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/BP6lCyvQrUJKyb1deM.c3A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8230cd721248043c3c5362450f0af7cc", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zFzAwv0VLpJHA1h4LC1yeA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8230cd721248043c3c5362450f0af7cc", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXAS"]}, {"uuid": "41036197-ab8f-3d1f-8d72-89b726917a8c", "title": "BTIG Raises Price Target on Exact Sciences to $75 From $65, Maintains Buy Rating", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/btig-raises-price-target-exact-160131438.html", "providerPublishTime": 1732636891, "type": "STORY", "relatedTickers": ["EXAS"]}]